View Post

Lisa Carey, MD, on Therapy for Early-Stage HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jeff Minerd From: Many patients overtreated, may benefit from de-escalation Advances in research and clinical practice have transformed HER2+ breast cancer from a disease with a poor prognosis to one with among the “best,” with relatively low relapse rates and deaths. However, as more complex and lengthy therapies have been developed to maximize outcomes, many patients are being …